Genetic Variants and Functional Pathways Associated with Resilience to Alzheimer’s Disease

Logan Dumitrescu, Emily R. Mahoney, Shubhabrata Mukherjee, Michael L. Lee, William S. Bush, Corinne D. Engelman, Qiongshi Lu, David W. Fardo, Emily H. Trittschuh, Jesse Mez, Catherine C. Kaczorowski, Hector Hernandez Saucedo, Keith F. Widaman, Rachel F. Buckley, Michael J Properzi, Elizabeth C. Mormino, Hyun‐Sik Yang, Tessa Harrison, Trey Hedden, Kwangsik Nho, Shea J. Andrews, Doug Tommet, Niran Hadad, R. Elizabeth Sanders, Douglas M. Ruderfer, Katherine A. Gifford, Annah M. Moore, Francis E. Cambronero, Xiaoyuan Zhong, Neha Raghavan, Badri N. Vardarajan, Margaret A. Pericak‐Vance, Lindsay A. Farrer, Li‐San Wang, Carlos Cruchaga, Gerard D. Schellenberg, Nancy J. Cox, Jonathan L. Haines, C. Dirk Keene, Andrew J. Saykin, Eric B. Larson, Reisa A. Sperling, Richard Mayeux, David A. Bennett, Julie A. Schneider, Paul K. Crane, Angela L. Jefferson, Timothy J. HohmanbioRxiv 2020 · DOI

Abstract

Approximately 30% of older adults exhibit the neuropathological hallmarks of Alzheimer’s disease (AD) without manifesting clinical signs of cognitive impairment. This phenomenon, known as cognitive resilience, suggests the existence of protective genetic factors that mitigate the impact of neurodegeneration. We performed a large-scale genome-wide association study (GWAS) involving 5,108 participants to identify the genetic architecture of resilience. Our findings reveal that cognitive resilience is genetically distinct from clinical AD risk and is associated with a novel locus on chromosome 18 near ATP8B1. Furthermore, resilience is linked to bile acid metabolism, neuropsychiatric traits, and epigenetic regulation in the prefrontal cortex, offering new avenues for therapeutic intervention.

Introduction

Alzheimer’s disease research has traditionally focused on the risk factors that lead to the accumulation of amyloid-β plaques and tau tangles. However, the observation that a significant portion of the elderly population remains cognitively intact despite high levels of pathology suggests that risk and resilience are two different biological processes. Understanding why some individuals are "resilient" to pathology is critical for developing treatments that preserve cognitive function even when the underlying disease cannot be fully cleared.

Quantifying Cognitive Resilience

To identify the genetic drivers of resilience, researchers utilized a "residual approach." Resilience was defined as the difference between an individual’s observed cognitive performance and the performance predicted by their age, sex, and actual amyloid pathology (measured via PET imaging or autopsy). By focusing on this residual, the study isolated the factors that allow for better-than-expected cognitive function.

Data were harmonized across 5,108 participants from four major longitudinal studies:

  • The A4 Study: A clinical trial for asymptomatic individuals with elevated amyloid.
  • ADNI: The Alzheimer’s Disease Neuroimaging Initiative.
  • ROS/MAP: The Religious Orders Study and Rush Memory & Aging Project.
  • ACT: The Adult Changes in Thought study.

Genetic Architecture and the Independence of Resilience

A primary finding of the study is that the genetic basis of resilience is distinct from the genetic basis of AD risk. Notably, neither resilience metric showed a significant genetic correlation with clinical AD risk. Furthermore, the APOE ε4 allele—the most potent genetic risk factor for AD—was not associated with resilience. This suggests that the biological pathways protecting the brain from the consequences of pathology are separate from those that drive the accumulation of the pathology itself.

Key Genetic Findings

The ATP8B1 Locus

The GWAS identified a genome-wide significant locus on chromosome 18 upstream of the gene ATP8B1 (index SNP rs2571244, $p = 2.3 \times 10^{-8}$). This association was particularly strong among individuals with normal cognition. ATP8B1 is traditionally known for its role in maintaining bile acid balance in the liver, suggesting a potential link between systemic metabolism and brain health.

Epigenetic Regulation

Functional annotation revealed that the lead variant (rs2571244) is significantly associated with DNA methylation levels in the prefrontal cortex. Specifically, it influences methylation at multiple CpG sites, including one just upstream of ATP8B1 ($p = 2 \times 10^{-13}$). This suggests that the genetic variant may exert its protective effects by modulating gene expression in a key brain region responsible for executive function and complex cognition.

The Gut-Liver-Brain Axis

Post-hoc analyses further supported the role of metabolism, showing that the top resilience-associated variant is linked to blood levels of five different bile acids. This adds to a growing body of evidence regarding the "gut-liver-brain axis," implying that metabolic health and bile acid signaling may be integral to neuroprotection.

Neuropsychiatric and Cognitive Correlations

Resilience metrics showed strong genetic correlations with several complex traits:

  • Education and Cognition: As expected, resilience was positively correlated with educational attainment and general cognitive performance ($p < 2.5 \times 10^{-20}$).
  • Mental Health: Novel correlations were found with neuropsychiatric conditions. Higher genetic risk for Obsessive-Compulsive Disorder (OCD) was associated with higher resilience, while higher genetic risk for ADHD was associated with lower resilience.
  • Lifestyle: Resilience was negatively correlated with smoking behaviors, specifically the number of cigarettes smoked per day.

Discussion and Future Directions

This study shifts the focus from the causes of neurodegeneration to the mechanisms of cognitive preservation. By identifying ATP8B1 and bile acid metabolism as potential players in resilience, the research opens the door to metabolic-based therapies.

However, limitations remain. The study population was primarily non-Hispanic white and highly educated, which may limit the generalizability of the findings. Future research should include more diverse cohorts and longitudinal assessments to understand how resilience evolves as pathology progresses. Additionally, while this study focused on amyloid, future work incorporating tau and vascular pathology may explain even more variance in cognitive outcomes.

Ultimately, the independence of resilience from APOE and clinical AD risk suggests that targeting resilience-specific pathways could provide a complementary approach to traditional AD treatments, helping patients maintain their quality of life despite the presence of disease pathology.

Summary updated

Abstract

Abstract Approximately 30% of older adults exhibit the neuropathologic features of Alzheimer’s disease (AD) without signs of cognitive impairment. Yet, little is known about the genetic factors that allow these potentially resilient individuals to remain cognitively normal in the face of substantial neuropathology. We performed a large, genome-wide association study (GWAS) of two previously validated metrics of cognitive resilience quantified using a latent variable modeling approach and representing better-than-predicted cognitive performance for a given level of neuropathology. Data were harmonized across 5,108 participants from a clinical trial of AD and three longitudinal cohort studies of cognitive aging. All analyses were run across all participants and repeated restricting the sample to individuals with normal cognition to identify variants at the earliest stages of disease. As expected, all resilience metrics were genetically correlated with cognitive performance and education attainment traits (p-values&lt;2.5×10 −20 ), and we observed novel correlations with neuropsychiatric conditions (p-values&lt;7.9×10 −4 ). Notably, neither resilience metric was genetically correlated with clinical AD (p-values&gt;0.42) nor associated with APOE (p-values&gt;0.13). In single variant analyses, we observed a genome-wide significant locus among participants with normal cognition on chromosome 18 upstream of ATP8B1 (index SNP rs2571244, MAF=0.08, p=2.3×10 −8 ). The top variant at this locus (rs2571244) was significantly associated with methylation in prefrontal cortex tissue at multiple CpG sites, including one just upstream of ATPB81 (cg19596477; p=2×10 −13 ). Overall, this comprehensive genetic analysis of resilience implicates a putative role of vascular risk, metabolism, and mental health in protection from the cognitive consequences of neuropathology, while also providing evidence for a novel resilience gene along the bile acid metabolism pathway. Furthermore, the genetic architecture of resilience appears to be distinct from that of clinical AD, suggesting that a shift in focus to molecular contributors to resilience may identify novel pathways for therapeutic targets.
BibTeX
@misc{dumitrescu2020genetic,
  author = {Logan Dumitrescu and Emily R. Mahoney and Shubhabrata Mukherjee and Michael L. Lee and William S. Bush and Corinne D. Engelman and Qiongshi Lu and David W. Fardo and Emily H. Trittschuh and Jesse Mez and Catherine C. Kaczorowski and Hector Hernandez Saucedo and Keith F. Widaman and Rachel F. Buckley and Michael J Properzi and Elizabeth C. Mormino and Hyun‐Sik Yang and Tessa Harrison and Trey Hedden and Kwangsik Nho and Shea J. Andrews and Doug Tommet and Niran Hadad and R. Elizabeth Sanders and Douglas M. Ruderfer and Katherine A. Gifford and Annah M. Moore and Francis E. Cambronero and Xiaoyuan Zhong and Neha Raghavan and Badri N. Vardarajan and Margaret A. Pericak‐Vance and Lindsay A. Farrer and Li‐San Wang and Carlos Cruchaga and Gerard D. Schellenberg and Nancy J. Cox and Jonathan L. Haines and C. Dirk Keene and Andrew J. Saykin and Eric B. Larson and Reisa A. Sperling and Richard Mayeux and David A. Bennett and Julie A. Schneider and Paul K. Crane and Angela L. Jefferson and Timothy J. Hohman and Timothy J. Hohman},
  title = {{Genetic Variants and Functional Pathways Associated with Resilience to Alzheimer’s Disease}},
  year = {2020},
  doi = {10.1101/2020.02.19.954651},
  howpublished = {bioRxiv},
}
Figure